F D C

F D C EBIT per Share

The EBIT per Share of F D C (FDC.NS) as of Oct 25, 2026 is 16.65 INR. In the previous year, EBIT per Share was 18.38 INR — a change of -9.42% (lower).

EBIT per Share

16.65INR

YoY

-9.42%

Last updated:

EBIT per Share of F D C is 2025 16.65 INR. EBIT per Share of F D C was 2024 18.38 INR. It decreases by -9.42% lower compared to the previous year.

The F D C EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2027 (e)
12.88 INR
Jan 1, 2028 (e)
16.54 INR
Jan 1, 2029 (e)
16.59 INR
Jan 1, 2030 (e)
18.18 INR
Jan 1, 2031 (e)
25.74 INR
Jan 1, 2032 (e)
23.62 INR
Jan 1, 2033 (e)
27.60 INR
Jan 1, 2034 (e)
31.18 INR
The F D C EBIT per Share history
YEAREBIT per ShareYoY
est31.18INR+12.98%
est27.60INR+16.85%
est23.62INR-8.24%
est25.74INR+41.58%
est18.18INR+9.59%
est16.59INR+0.32%
est16.54INR+28.43%
est12.88INR-22.66%
16.65INR-9.42%
18.38INR+41.14%
13.02INR-0.14%
13.04INR-24.99%
17.39INR+0.15%
17.36INR+51.88%
11.43INR+0.93%
11.33INR-9.14%
12.47INR+4.07%
11.98INR+21.72%
9.84INR-12.23%
11.21INR+33.36%
8.41INR+4.09%
8.08INR-3.02%
8.33INR+3.41%
8.05INR+57.12%
5.13INR+68.79%
3.04INR-18.65%
3.73INR+20.03%
3.11INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

F D C Stock analysis

What does F D C do? FDC Ltd. generates revenue through the manufacturing and distribution of pharmaceutical generics, formulations, and active pharmaceutical ingredients (APIs). The company produces specialized products such as oral rehydration salts (ORS) and functional foods and beverages, targeting therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. Its branded products like Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm are sold to healthcare providers and consumers across these segments. The company's APIs, including Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate, and Timolol Maleate, support its formulation business. FDC Ltd. distributes its products through its manufacturing plants, serving both domestic and international markets with a focus on cost-effective generic medicines and specialized formulations. FDC Ltd. targets healthcare providers, hospitals, and retail pharmacies as key buyers of its branded pharmaceuticals and functional products. The company's product portfolio spans multiple therapeutic areas, with brands like Zifi for respiratory conditions and Electral for rehydration, catering to diverse consumer needs in the Indian pharmaceutical market. F D C is one of the most popular companies on Eulerpool.

Frequently Asked Questions about F D C stock

EBIT per Share of F D C is 16.65 INR in 2025.

EBIT per Share of F D C changed from 18.38 INR to 16.65 INR, representing a -9.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share F D C since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — F D C

All Key Metrics — F D C